透過您的圖書館登入
IP:3.16.130.38
  • 期刊
  • OpenAccess

Virtual screening by targeting proteolytic sites of furin and TMPRSS2 to propose potential compounds obstructing the entry of SARS-CoV-2 virus into human host cells

摘要


Background and aim: The year 2020 begins with the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that cause the disease COVID-19, and continue till today. As of March 23, 2021, the outbreak has infected 124,313,054 worldwide with a total death of 2,735,707. The use of traditional medicines as an adjuvant therapy with western drugs can lower the fatality rate due to the COVID-19. Therefore, in silico molecular docking study was performed to search potential phytochemicals and drugs that can block the entry of SARS-CoV-2 into host cells by inhibiting the proteolytic cleavage activity of furin and TMPRSS2. Experimental procedure: The protein-protein docking of the host proteases furin and TMPRSS2 was carried out with the virus spike (S) protein to examine the conformational details and residues involved in the complex formation. Subsequently, a library of 163 ligands containing phytochemicals and drugs was virtually screened to propose potential hits that can inhibit the proteolytic cleavage activity of furin and TMPRSS2. Results and conclusion: The phytochemicals like limonin, gedunin, eribulin, pedunculagin, limonin glycoside and betunilic acid bind at the active site of both furin and TMPRSS2. Limonin and gedunin found mainly in the citrus fruits and neem showed the highest binding energy at the active site of furin and TMPRSS2, respectively. The polyphenols found in green tea can also be useful in suppressing the furin activity. Among the drugs, the drug nafamostat may be more beneficial than the camostat in suppressing the activity of TMPRSS2.

參考文獻


Fuzimoto AD, Isidoro C. The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - additional weapons in the fight against the COVID-19 pandemic? J Tradit Complement Med. 2020;10(4):405-419. https://doi.org/10.1016/j.jtcme.2020.05.003
Abdel-Moneim AS, Abdelwhab EM. Evidence for SARS-CoV-2 infection of animal hosts. Pathogens. 2020;9(7):529. https://doi.org/10.3390/pathogens9070529
Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020;30(7):1346-1351. https://doi.org/10.1016/j.cub.2020.03.022. e2
Naqvi AAT, Fatima K, Mohammad T, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2020;1866(10), 165878. https://doi.org/10.1016/j.bbadis.2020.165878
Zaki A, Al-Karmalawy A, El-Amier Y, Ashour A. Molecular docking reveals the potential of Cleome amblyocarpa isolated compounds to inhibit COVID-19 virus main protease. New J Chem. 2020;44(39):16752-16758. https://doi.org/10.1039/d0nj03611k

被引用紀錄


Isidoro, C., Chang, A. C. F., & Sheen, L. Y. (2022). Natural products as a source of novel drugs for treating SARS-CoV2 infection. Journal of Traditional and Complementary Medicine, 12(1), 1-5. https://doi.org/10.1016/j.jtcme.2022.02.001
Vardhan, S., & Sahoo, S. K. (2022). Exploring the therapeutic nature of limonoids and triterpenoids against SARS-CoV-2 by targeting nsp13, nsp14, and nsp15 through molecular docking and dynamics simulations. Journal of Traditional and Complementary Medicine, 12(1), 44-54. https://doi.org/10.1016/j.jtcme.2021.12.002
Singh, R., Bhardwaj, V. K., Sharma, J., Purohit, R., & Kumar, S. (2022). In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors. Journal of Traditional and Complementary Medicine, 12(1), 35-43. https://doi.org/10.1016/j.jtcme.2021.05.005

延伸閱讀